ArticleBMC medical genomics2025
Arsenic sulfide alleviates the progression of liver cancer malignancy by inhibiting the expression of TLCD1 in mice.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TLCD1 correlates with malignant progression of hepatocellular carcinoma and activation of the ERK signaling cascade.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Liver cancer is the leading cause of cancer deaths worldwide and is the only cancer type among the five deadliest cancers with an increasing incidence each year. The prognosis of liver cancer is poor and no effective treatment for this cancer to date. Arsenic sulfide has been found to be effective in the treatment of hematological malignancies but its therapeutic outcomes and associated mechanisms in liver cancer remain unknown. In this study, we found that arsenic sulfide treatment could effectively inhibit the proliferation, migration and promotion of apoptosis of hepatoma cell lines, and remarkably alleviated the progression of hepatocellular carcinoma in mouse models. Transcriptomic analysis of the HepG2 cell line treated with arsenic sulfide showed that arsenic sulfide inhibited the proliferation of hepatoma cells by inhibiting the expression of Triacylglycerol and Lipid Catabolism Deficient 1 (TLCD1), thereby alleviating the malignant progression of hepatocellular carcinoma. This study provides a molecular basis for arsenic sulfide in the treatment of liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.